Cubist Systematic Strategies, LLC Larimar Therapeutics, Inc. Transaction History
Cubist Systematic Strategies, LLC
- $15.6 Billion
- Q1 2025
A detailed history of Cubist Systematic Strategies, LLC transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 354,232 shares of LRMR stock, worth $1.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
354,232
Previous 233,873
51.46%
Holding current value
$1.3 Million
Previous $893,000
14.78%
% of portfolio
0.0%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding LRMR
# of Institutions
121Shares Held
65MCall Options Held
93.5KPut Options Held
68K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$77.7 Million1.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$22.1 Million0.27% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$20.4 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.78MShares$17.5 Million5.31% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$12.5 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $158M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...